Story · Medicine & Biotech

Ziltivekimab cuts inflammation but not CV events in ZEUS

1 outlet · first reported by Healio 4d ago

Coverage, in order

  1. 4d ago
    Healio indie
    Ziltivekimab cuts inflammation but not CV events in ZEUS

    CHICAGO — Ziltivekimab, a novel interleukin-6 inhibitor, lowered inflammatory markers but not major adverse CV events compared with placebo among adults with atherosclerotic CVD and chronic kidney disease in the ZEUS trial. “Cardiovascular inflammation is highly prevalent. It remains a…

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.